Phase 3/4 Study of a Recombinant Protein-Free Factor VIII (rAHF-PFM): Comparison of Continuous Infusion Versus Intermittent Bolus Infusion in Hemophilia A Subjects Undergoing Major Orthopedic Surgery

Hemophilia A Clinical Trial

Official title:

Antihemophilic Factor (Recombinant) Plasma/Albumin-Free Method (rAHF PFM): A Phase 3/4, Prospective, Controlled, Randomized, Multi-Center Study to Compare the Efficacy and Safety of Continuous Infusion (CI) Versus Intermittent Bolus Infusion (BI) in Subjects With Severe or Moderately Severe Hemophilia A Undergoing Major Orthopedic Surgery

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00357656
• Other study ID #: 060402
• Secondary ID: 2005-005697-71
• Status: Completed
• Phase: Phase 4
• Start date: May 29, 2006
• Est. completion date: December 9, 2015

Study information

• Verified date: April 2021
• Source: Takeda
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to compare the hemostatic efficacy and safety of continuous infusion versus intermittent bolus infusion in the peri- and post-operative setting, employing rAHF-PFM, a recombinant antihemophilic factor manufactured without added human or animal proteins, in previously treated patients with severe or moderately severe hemophilia A (baseline factor VIII level <= 2% of normal) who are undergoing unilateral major orthopedic surgery that requires drain placement. The total study period per subject (from consent to study completion) will vary from approximately 9 to 26 weeks and will involve clinical and laboratory assessments.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 85
• Est. completion date: December 9, 2015
• Est. primary completion date: October 1, 2015
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 70 Years

Eligibility

Inclusion Criteria:

• The subject or the subject's legally authorized representative has provided signed informed consent.

• The subject is within 18 to 70 years of age.

• The subject has severe or moderately severe hemophilia A, defined by a baseline factor VIII level <= 2% of normal, as tested at screening. A subset of 15 subjects per group must have baseline factor VIII levels < 1% of normal.

• The aPTT must be within the range of normal after administration of FVIII concentrate, as determined in the preoperative pharmacokinetic evaluation, or as documented in the medical history, if available.

• The subject is scheduled to undergo an elective unilateral major orthopedic surgery that requires drain placement.

• The subject was previously treated with factor VIII concentrate(s) for a minimum of at least 150 exposure days (as estimated by the investigator) prior to study entry.

• Human immunodeficiency virus (HIV) positive subjects must be immunocompetent as determined with a CD4 count >= 200 cells/mm³ (CD4 count at screening), but HIV negative subjects with a CD4 count < 200 cells/mm³ qualify, if immunocompetency is documented.

• The subject has a life expectancy of at least 28 days from the day of surgery.

Exclusion Criteria:

• The subject has a detectable factor VIII inhibitor at screening, with a titer >= 0.4 BU (Nijmegen modification of the Bethesda assay) in the central laboratory.

• The subject has a history of factor VIII inhibitors with a titer >= 0.4 BU (by Nijmegen assay) or >= 0.5 BU (by Bethesda assay) at any time prior to screening.

• The subject is scheduled to undergo any other concurrent minor or major surgery during the course of the study. The placement of central venous lines and the performance of fine needle aspiration biopsies are permitted.

• Excluding hemophilia-related physical impairments, the subject is assigned to NYHA class >= III according to the New York Heart Association (NYHA).

• The subject has an abnormal renal function (serum creatinine > 1.5 mg/dL).

• The subject has active hepatic disease (alanine aminotransferase [ALT] or aspartate aminotransferase [AST] levels > 5 times the upper limit of normal).

• The subject has severe chronic liver disease as evidenced by, but not limited to, any of the following: International Normalized Ratio (INR) > 1.4, hypoalbuminemia, portal vein hypertension including presence of otherwise unexplained splenomegaly and history of esophageal varices.

• The subject has clinical and/or laboratory evidence of abnormal hemostasis from causes other than hemophilia A (e.g., late-stage chronic liver disease, immune thrombocytopenia purpura).

• The subject is currently receiving, or is scheduled to receive during the course of the study, an immunomodulating drug other than anti-retroviral chemotherapy (e.g., alpha-interferon, corticosteroid agents at a dose equivalent to hydrocortisone greater than 10 mg/day).

• The subject has a known hypersensitivity to mouse or hamster proteins.

• The subject has received another investigational drug study within 30 days prior to screening and/or is scheduled to receive additional investigational drug during the course of the trial in the context of another investigational study.

• The subject is identified by the investigator as being unable or unwilling to cooperate with study procedures.

Related Conditions & MeSH terms

• Hemophilia A

Intervention

Drug:
• Recombinant Protein-Free Factor VIII (rAHF-PFM)
An initial loading dose will be administered intravenously over a period <= 5 minutes (maximum of infusion rate of 10 mL/minute) within 60 minutes prior to surgery dose in order to maintain a minimum target FVIII level of at least 80% of normal. CI will start prior to surgery as soon as the loading dose has been administered, at a rate calculated according to a formula provided by the sponsor. All study product must be administered with a syringe pump running at an infusion rate according to the dosing regimen, but always >= 0.4 mL/h.
• Recombinant Protein-Free Factor VIII (rAHF-PFM)
The treatment schedule for intermittent BI of rAHF-PFM will begin with the administration of the loading dose according to the dose recommendations provided by the sponsor. If required by the hemostatic challenge, additional boluses may be administered after a blood sample for FVIII determination has been drawn. All infusions of rAHF PFM will be given over a period <= 5 minutes (maximum infusion rate, 10 mL/min).

Locations

Country	Name	City	State
Austria	University Hospital for Internal Medicine I (Hematology/Hemostaseology)	Vienna
Belgium	Cliniques Universitaires St. Luc, Haematology Department	Brussels
Belgium	University Hospital Gasthuisberg	Leuven
France	Hôpital Edouard Herriot	Lyon
Hungary	State Health Centre, National Hemophilia Centre	Budapest
Hungary	University of Debrecen, 2nd Dept of Internal Medicine	Debrecen
Hungary	PTE ÁOK I. Internal Medical Clinic, Dept of Hematology	Pécs
Italy	Centro Emofilia e Trombosi "Angelo Bianchi Bonomi"	Milano
Italy	Department of Clinical & Experimental Medecine, AOU Federico II	Naples
Netherlands	AMC Medical Research BV, Department of Vascular Medicine	Amsterdam
Netherlands	University Medical Centre Groningen	Groningen
Netherlands	Academic Hospital Maastricht	Maastricht
Norway	Rikshospitalet	Oslo
Poland	Krakowskie Centrum Rehabilitacji	Krakow
Poland	Instytut Hematologii i Transfuzjologii, Klinika Zaburzen Hemostazy i Chorób Wewnetrznych	Warsaw
Portugal	Centro Hospitalar de Coimbra	Coimbra
Portugal	Hospital Santo António	Porto
Romania	Fundeni Clinical Institute, Clinical Laboratory "St. Berceanu" Hematology and Bone Marrow Transplantation Department	Bucharest
Romania	National Blood Transfusion Institute	Bucharest
Romania	"Louis Turcanu" Emergency Clinical Children´s Hospital, 3rd Pediatrics Department, Hemophilia Center	Timisoara
Russian Federation	Regional Hemophilia Center	Kirov
Russian Federation	Hematology Research Center under Russian Academy of Medical Sciences, Department of Reconstructive Orthopedic Surgery for Hemophilia Patients	Moscow
Russian Federation	Russian Research Institute of Hematology and Transfusiology, Department of Surgical Hematology and Angiology	St. Petersburg
Spain	Hospital Vall d´Hebron, Servei d´Hemofilia	Barcelona
Spain	Hospital Universitario La Fe	Valencia
Sweden	University Hospital MAS, Department for Coagulation Disorders	Malmo
United States	Johns Hopkins Medical Institutions	Baltimore	Maryland
United States	Brigham and Women´s Hospital	Boston	Massachusetts
United States	Rush Presbyterian St. Lukes	Chicago	Illinois
United States	University Hospitals of Cleveland	Cleveland	Ohio
United States	Penn State Milton S. Hershey Medical Center	Hershey	Pennsylvania
United States	The University of Texas Health Science Center at Houston Medical School	Houston	Texas
United States	Los Angeles Orthopaedic Hospital	Los Angeles	California
United States	James Graham Brown Cancer Center	Louisville	Kentucky
United States	Tulane University	New Orleans	Louisiana
United States	Georgetown University	Washington	District of Columbia

Sponsors (2)

Lead Sponsor	Collaborator
Baxalta now part of Shire	Baxalta Innovations GmbH, now part of Shire

Countries where clinical trial is conducted

United States,  Austria,  Belgium,  France,  Hungary,  Italy,  Netherlands,  Norway,  Poland,  Portugal,  Romania,  Russian Federation,  Spain,  Sweden, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Cumulative Packed Red Blood Cell (PRBC) Volume in the Drainage Fluid During the First 24 Hours Following Surgery in Subjects Receiving ADVATE (rAHF-PFM) by Bolus (BI) or Continuous Infusion (CI)	Drainage fluid volume was to be measured cumulatively and recorded every 8 hours ± 30 minutes during the first 24 hours following surgery. Unit of measure: Tera per Liter is the PRBC concentration in 10^12 units per 1 liter of drainage fluid.	During the first postoperative 24 hours every 8 hours ± 30 minutes the drainage fluid was to be recorded..
Secondary	Actual Postoperative Blood Loss During the First 24 Hours Compared With the Average Blood Loss as Predicted Preoperatively by the Operating Surgeon	Drainage fluid volume was to be measured cumulatively and recorded every 8 hours ± 30 minutes during the first 24 hours following surgery. Prior to surgery, the operating surgeon was to predict the estimated duration of surgery and the volume (mL) of the estimated expected blood loss for the surgery in a hemostatically normal individual of the same sex, age, and stature as the study subject 1) for the intraoperative procedure (defined as the time period from incision to application of compressive dressing and release of tourniquet, if applicable), 2) for the first 24 hours postoperatively, and 3) for the postoperative period until drain removal, if drainage continued beyond 24 hours. Units: Milliliter of blood	During the first 24 postoperative hours blood loss was measured every 8 hours ± 30 minutes
Secondary	Actual Postoperative Blood Loss Compared to the Expected Average Blood Loss Until Drain Removal as Predicted Preoperatively by the Surgeon	The total blood loss for the postoperative period (from end of surgery until drain removal) was adjusted for the expected blood loss by applying a log-transformation of the blood loss data. The drainage volume was measured every 8 hours +/- 30 minutes during the first 24 hours. If the drainage continued beyond 24 hours, the PRBC volume and hemoglobin was to be measured cumulatively every 24 hours or whenever the drainage bottle was emptied and at the time of drain removal. Prior to surgery, the operating surgeon was to predict the estimated duration of surgery and the volume (mL) of the estimated expected blood loss for the surgery in a hemostatically normal individual of the same sex, age, and stature as the study subject for the first 24 hours postoperatively, and for the postoperative period until drain removal, if drainage continued beyond 24 hours. Units: Milliliter of blood	From end of surgery (application of compressive dressing and release of tourniquet, if applicable) until drain removal (up to postoperative day 7).
Secondary	Number of Bleeding Episodes During Treatment With Continuous or Bolus Infusion	To simplify the results below: Bleeding episodes were reported for 4 subjects (3 subjects on bolus infusion: 2 in Stratum A and 1 in Stratum B, and 1 subject on continuous infusion/Stratum B). The 4 subjects had 1 bleeding episode each. No bleeding episodes were reported for Stratum C.	Through Postoperative Day 7
Secondary	Number of Units of Packed Red Blood Cells Transfused		During the first postoperative 24 hours
Secondary	Number of Adverse Events Related to the Administration of the Study Product.	All AEs from the first study drug exposure until the study completion/discontinuation date were to be recorded. Each AE was to be evaluated by the investigator for causal relationship (i.e., unrelated, possibly related or probably related) to the study product.	From first study drug exposure until study completion/discontinuation (approximately 9-26 weeks per subject)
Secondary	Incidence of Factor VIII Inhibitory Antibody (=0.4 Bethesda Units Using the Nijmegen Modification of the Bethesda Assay Formation)	Number of participants that developed Factor VIII inhibitory antibody during the study.	Throughout the study period of approximately 9-26 weeks per participant